Category: Psychiatry

Nov 06

Baclofen as treatment for alcohol use disorders

Garbutt et al. Alcohol Clin Exp Res 2010 Nov;34(11):1849-57
Baclofen cannot be recommended as a routine treatment for alcohol use disorders. The quality of the evidence is low overall.

Jun 14

Metformin as prevention in people taking antipsychotic medication

Zheng et al. J Clin Psychopharmacol 2015 Oct;35(5):499-509.
The effect of metformin on cardiovascular disease in people living without diabetes on long-term antipsychotic medication is unknown.

Nov 07

St John’s wort for minor depression

Rapaport MH, et al. Journal of Psychiatric Research 2011; 45(7): 931-941
St John’s wort is probably ineffective for minor depression.

Sep 28

Can exercise be a treatment for depression?

Chalder M, et al. BMJ 2012; 344:e2758
Recommending structured moderate or vigorous exercise in addition to routine GP care is not effective for the treatment of depression.

Mar 23

Cannabis use and earlier onset of psychosis

Large M, et al. Cannabis use and earlier onset of psychosis. Arch Gen Psychiatry 2011: published online 7 February 2011
Cannabis may be causally related to psychotic illness but the evidence remains unclear.

Mar 02

DHA on maternal depression and neurodevelopment

Makrides M, et al. Effect of DHA supplementation during pregnancy on maternal depression and neurodevelopment of young children: a randomized controlled trial. JAMA. 2010; 304(15): 1675-1683
DHA supplements in the later half of pregnancy are not associated with improvements in maternal depression or infant neurodevelopment.

Feb 23

Antipsychotics and the risk of venous thromboembolism

Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ 2010;341:c4245.
Antipsychotic drugs are associated with a 32% increased risk of venous thromboembolism.

Jan 19

Reboxetine for acute treatment of major depression

Eyding D, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and SSRI. BMJ 2010;341:c4737
Reboxetine is no more effective than placebo for major depressive disorder.